MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 449, Issue 1, 2014, Pages 49-54

  Liu, Tongxin ^a   Li, Qi ^a   Sun, Quanquan ^a   Zhang, Yuqin ^a   Yang, Hua ^a   Wang, Rong ^a   Chen, Longhua ^a   Wang, Wei ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

MET inhibitor; Nasopharyngeal carcinoma; Radiosensitivity

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IONIZING RADIATION; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

MET INHIBITOR; NASOPHARYNGEAL CARCINOMA; RADIOSENSITIVITY;

CELL LINE, TUMOR; CELL PROLIFERATION; CHEMORADIOTHERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RADIATION TOLERANCE; SULFONES; TREATMENT OUTCOME; UP-REGULATION;

EID: 84901747937     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.147     Document Type: Article

References (33)

1. H.H. Loong, B.B. Ma, and A.T. Chan Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer Hematol. Oncol. Clin. North Am. 22 2008 1267-1278, x
2. W.I. Wei, and J.S. Sham Nasopharyngeal carcinoma Lancet 365 2005 2041 2054 (Pubitemid 40812341)
3. A.W. Lee, W.M. Sze, J.S. Au, S.F. Leung, T.W. Leung, D.T. Chua, B.C. Zee, S.C. Law, P.M. Teo, S.Y. Tung, D.L. Kwong, and W.H. Lau Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience Int. J. Radiat. Oncol. Biol. Phys. 61 2005 1107 1116 (Pubitemid 40340904)
4. E.E. Vokes, D.N. Liebowitz, and R.R. Weichselbaum Nasopharyngeal carcinoma Lancet 350 1997 1087 1091 (Pubitemid 27437868)
5. H. Ali, and M. Al-Sarraf Chemotherapy in advanced nasopharyngeal cancer Oncology (Williston Park) 14 2000 1223 1230 (discussion 1232-7, 1239-42)
6. Y. Bensouda, W. Kaikani, N. Ahbeddou, R. Rahhali, M. Jabri, H. Mrabti, H. Boussen, and H. Errihani Treatment for metastatic nasopharyngeal carcinoma Eur. Ann. Otorhinolaryngol. Head Neck Dis. 128 2011 79 85
7. F. Caponigro, F. Longo, F. Ionna, and F. Perri Treatment approaches to nasopharyngeal carcinoma: a review Anticancer Drugs 21 2010 471 477
8. B.B. Ma, and A.T. Chan Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma Expert Rev. Anticancer Ther. 6 2006 383 394 (Pubitemid 44192920)
9. S.L. Chan, and B.B. Ma Novel systemic therapeutic for nasopharyngeal carcinoma Expert Opin. Ther. Targets 16 Suppl. 1 2012 S63 S68
10. N.Y. Lee, Q. Zhang, D.G. Pfister, J. Kim, A.S. Garden, J. Mechalakos, K. Hu, Q.T. Le, A.D. Colevas, B.S. Glisson, A.T. Chan, and K.K. Ang Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial Lancet Oncol. 13 2012 172 180
11. C.R. Maroun, and T. Rowlands The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance Pharmacol. Ther. 142 2014 316 338
12. C. Birchmeier, W. Birchmeier, E. Gherardi, and W.G. Vande Met, metastasis, motility and more Nat. Rev. Mol. Cell Biol. 4 2003 915 925 (Pubitemid 37493640)
13. Q. Zeng, S. Chen, Z. You, F. Yang, T.E. Carey, D. Saims, and C.Y. Wang Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B J. Biol. Chem. 277 2002 25203 25208 (Pubitemid 34951827)
14. R.M. Anderson, M. Delous, J.A. Bosch, L. Ye, M.A. Robertson, D. Hesselson, and D.Y. Stainier Hepatocyte growth factor signaling in intrapancreatic ductal cells drives pancreatic morphogenesis PLoS Genet. 9 2013 e1003650
15. Y.J. Kim, H. Go, H.G. Wu, Y.K. Jeon, S.W. Park, and S.H. Lee Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy Head Neck 33 2011 1458 1466
16. Y.J. Kim, J.S. Choi, J. Seo, J.Y. Song, S.E. Lee, M.J. Kwon, M.J. Kwon, J. Kundu, K. Jung, E. Oh, Y.K. Shin, and Y.L. Choi MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer Int. J. Cancer 134 2014 2424 2436
17. O.O. Ogunwobi, W. Puszyk, H.J. Dong, and C. Liu Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma PLoS One 8 2013 e63765
18. V. Bhardwaj, T. Cascone, M.A. Cortez, A. Amini, J. Evans, R.U. Komaki, J.V. Heymach, and J.W. Welsh Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy Cancer 119 2013 1768 1775
19. H. Yang, H.W. Lee, Y. Kim, Y. Lee, Y.S. Choi, K.H. Kim, J. Jin, J. Lee, K.M. Joo, and D.H. Nam Radiosensitization of brain metastasis by targeting c-MET Lab. Invest. 93 2013 344 353
20. H. Yu, X. Li, S. Sun, X. Gao, and D. Zhou C-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation Biochem. Biophys. Res. Commun. 427 2012 659 665
21. F. De Bacco, P. Luraghi, E. Medico, G. Reato, F. Girolami, T. Perera, P. Gabriele, P.M. Comoglio, and C. Boccaccio Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer J. Natl. Cancer Inst. 103 2011 645 661
22. L.M. Green, J.L. Reade, and C.F. Ware Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines J. Immunol. Methods 70 1984 257 268 (Pubitemid 14111307)
23. S. Yano, W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe, T. Nakamura, and S. Sone Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res. 68 2008 9479 9487
24. G. Xie, J. Zhan, Y. Tian, Y. Liu, Z. Chen, C. Ren, Q. Sun, J. Lian, L. Chen, J. Ruan, C. Ye, A. Sun, and Y. Yuan Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistance Cancer Lett. 316 2012 53 61
25. B. Fertil, H. Dertinger, A. Courdi, and E.P. Malaise Mean inactivation dose: a useful concept for intercomparison of human cell survival curves Radiat. Res. 99 1984 73 84 (Pubitemid 14095136)
26. R. Prevo, E. Deutsch, O. Sampson, J. Diplexcito, K. Cengel, J. Harper, P. O'Neill, W.G. McKenna, S. Patel, and E.J. Bernhard Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity Cancer Res. 68 2008 5915 5923
27. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res. 61 2001 3986 3997 (Pubitemid 32720961)
28. S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, A.B. Hjelmeland, M.W. Dewhirst, D.D. Bigner, and J.N. Rich Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760 (Pubitemid 44949604)
29. A. Sallmyr, J. Fan, and F.V. Rassool Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair Cancer Lett. 270 2008 1 9
30. R.E. Meyn, A. Munshi, J.V. Haymach, L. Milas, and K.K. Ang Receptor signaling as a regulatory mechanism of DNA repair Radiother. Oncol. 92 2009 316 322
31. L.Q. Xie, L.J. Bian, Z. Li, Y. Li, Z.X. Li, and B. Li Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma Ann. Surg. Oncol. 17 2010 1927 1936
32. L.Q. Xie, L.J. Bian, Z. Li, Y. Li, and Y.J. Liang Co-elevated expression of hepatocyte growth factor and interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma Oncol. Rep. 23 2010 141 150
33. J.P. Eder, W.G. Vande, S.A. Boerner, and P.M. LoRusso Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin. Cancer Res. 15 2009 2207 2214